Email Alert | RSS

Journal of Peking University(Health Sciences) ›› 2019, Vol. 51 ›› Issue (3): 477-486. doi: 10.19723/j.issn.1671-167X.2019.03.015

Previous Articles     Next Articles

Preparation and characterization of paclitaxel microspheres in situ gel and its antitumor efficacy by local injection

Ying ZHAN1,Yi-tian DU1,Zhen-zhen YANG1,Chun-li ZHANG2,Xian-rong QI1△()   

  • Received:2019-03-22 Online:2019-06-18 Published:2019-06-26
  • Supported by:
    Supported by the National Natural Science Foundation of China (81673365) and the Fundamental Research Funds for the Central Universities: Peking University Medicine Seed Fund for Interdisciplinary Research (BMU2018MX009)

RICH HTML

 29   

PDF (PC)

333

Abstract: Objective: The current difficulties in the treatment of tumor include repeated administration and high recurrence rate after tumor resection. In order to reduce the number of doses, avoid side effects of chemotherapeutic drugs, suppress tumor growth and delay tumor recurrence after surgery, a temperature-sensitive in situ gel with paclitaxel microspheres (PTX/M gel) was prepared. PTX/M gel was administered by intratumoral injection once a month.Methods: First of all, paclitaxel microspheres (PTX/M) were prepared by emulsion solvent evaporation method. A laser particle size distribution analyzer was used to investigate the size, distribution, specific surface area of microspheres. Paclitaxel content was determined by high performance liquid chromatography (HPLC). Then encapsulation efficiency of paclita-xel was calculated and in vitro release characteristics were studied. Secondly, PTX/M gel was prepared by cold dissolution method. The phase transition temperature, elastic modulus, dissolution curve, correlation between dissolution and release were measured. Finally, U87 MG and 4T1 subcutaneous tumor mo-dels were established respectively to study the efficacy of PTX/M gel in suppressing tumor growth and delaying tumor recurrence after surgery.Results: The median diameter of the selected PTX/M was (32.24±1.09) μm, the specific surface area was (206.61±10.23) m 2/kg, the encapsulation efficiency was 85.29%±1.34%, and the cumulative release percentage of paclitaxel from PTX/M was 33.56%±3.33% in one month. Phase transition temperature of PTX/M gel was 33 ℃. The elastic modulus of PTX/M gel at 25 ℃ and 37 ℃ were 4.2×10 3 Pa and 18×10 3 Pa, respectively. The gel could stay in the body for up to 48 hours. It could be seen from the results of animal experiments that were compared with the saline group and the Taxol group, and the tumor-bearing mice of the PTX/M gel group had the slowest tumor growth (P<0.05). Similarly, in the tumor recurrence experiments, the mice of PTX/M gel group had the latest tumor recurrence after surgery. Conclusion: As a local sustained-release preparation, PTX/M gel can effectively suppress tumor growth and delay postoperative recurrence of tumors. It has potential advantages in tumor treatment.

Key words: Paclitaxel, Microspheres, In situ gel, Delayed-action preparations, Treatment outcome

CLC Number: 

  • R944.1

Figure 1

The particle diameter distribution of PTX/M 16 (A), PTX/M 10 (B), PTX/M 06 (C) Blue line represents cumulative distribution and red line reresents difference distribution."

Table 1

Comparison of particle diameter, SSA, EE, DL among PTX/M 16, PTX/M 10 and PTX/M 06"

Items PTX/M 16 PTX/M 10 PTX/M 06
Size/μm 23.17±0.6 32.24±1.09 99.74±21.61
SSA/(m2/kg) 227.97±5.78 206.61±10.23 113.68±9.94
EE/% 74.55±2.26 85.29±1.34 95.82±1.95
DL/% 15.71±0.40 17.57±0.23 19.32±0.32

Figure 2

Percentage of accumulated release of PTX from PTX/M 16, PTX/M 10 and PTX/M 06, respectively PTX, paclitaxel; PTX/M, paclitaxel microspheres. Data are presented as the x?±s (n=3)."

Figure 3

SEM micrographs of PTX/M (A, B) and degraded PTX/M after 30 days (C, D)"

Table 2

Phase transition temperature of gel when the concentration of Poloxamer 188 was changed"

Concentration of Poloxamer 188/% Phase transition temperature/℃
Blank gel PTX/M gel
1.8 32 ≤25
2.2 35 30
2.6 37 33
3.0 39 36
3.4 40 37
3.6 42 39

Figure 4

Modulus of blank gel and PTX/M gel at 25 ℃, 37 ℃"

Figure 5

Accumulated erosion of blank gel and PTX/M gel PTX/M, paclitaxel microspheres. Data are presented as the x?±s (n=3)."

Figure 6

Percentage of cumulative release of PTX/M from PTX/M gel (A) and correlation between PTX/M gel release and dissolution (B) PTX/M, paclitaxel microspheres. Data are presented as the x?±s (n=3)."

Figure 7

Changes of saline (A) and gel (B) labeled with trypan blue were injected into water at 37 ℃; Photographs of gel injected into the back of the mouse for 2 h, 4 h, 6 h, 12 h, 24 h, 48 h and control for 2 h (C)"

Figure 8

A, tumor growth curve of U87MG-bearing mice (*P=0.02, **P=0.002, vs. Control); B, relative body weight curve; C, percent of organ relative weight (Normal represents the organ index of normal nude mice[12]); D, HE staining of major organ tissues (100×) Data are presented as the x?±s (n=10). Data are presented as the x?±s (n=6)."

Figure 9

A, tumor growth curve of 4T1-bearing mice (*P=0.003, vs. Control); B-D, tumor growth curve of each mouse in Control, PTX/M gel, Taxol groups; E, relative body weight-time curve of mice; F, proportion of different degrees of lung metastasis in mice"

Figure 10

A, tumor free rate after surgery in different drug-administered groups; B-D, tumor growth curve of each mouse after surgery in control, PTX/M gel, Taxol groups; E, survival curve of mice with surgery; F, proportion of different degrees of lung metastasis in mice"

[1] Gladson CL, Prayson RA, Liu WM . The pathobiology of glioma tumors[J]. Annu Rev Pathol, 2010,5(1):33-50.
doi: 10.1146/annurev-pathol-121808-102109
[2] Fan L, Strasser-Weippl K, Li JJ , et al. Breast cancer in China[J]. Lancet Oncol, 2014,15(7):e279-e289.
doi: 10.1016/S1470-2045(13)70567-9
[3] Marupudi N . Paclitaxel: a review of adverse toxicities and novel delivery strategies[J]. Expert Opin Drug Saf, 2007,6(5):609-621.
doi: 10.1517/14740338.6.5.609
[4] Floyd JA, Galperin A, Ratner BD . Drug encapsulated polymeric microspheres for intracranial tumor therapy: A review of the literature[J]. Adv Drug Deliv Rev, 2015,91:23-37.
doi: 10.1016/j.addr.2015.04.008
[5] 顼佳音, 杨洪军, 熊欣 , 等. 常见温度敏感型原位凝胶载体的研究进展[J]. 中国实验方剂学杂志, 2011,17(2):252-257.
[6] Elkharraz K, Faisant N, Guse C , et al. Paclitaxel-loaded micro-particles and implants for the treatment of brain cancer: Preparation and physicochemical characterization[J]. Int J Pharm, 2006,314(2):127-136.
doi: 10.1016/j.ijpharm.2005.07.028
[7] Dumortier G, Grossiord JL, Agnely F , et al. Areview of poloxamer 407 pharmaceutical and pharmacological characteristics[J]. Pharm Res, 2006,23(12):2709-2728.
doi: 10.1007/s11095-006-9104-4
[8] Shelke S, Shahi S, Jalalpure S , et al. Formulation and evaluation of thermoreversible mucoadhesive in situ gel for intranasal delivery of Naratriptan hydrochloride[J]. J Drug Deliv Sci Technol, 2015,29:238-244.
doi: 10.1016/j.jddst.2015.08.003
[9] Pluta J, Karolewicz B . In vitro studies of the properties of thermosensitive systems prepared on Pluronic F-127 as vehicles for me-thotrexate for delivery to solid tumours[J]. Polim Med, 2006,36(3):37-53.
[10] Feng L, Qi XR, Zhou XJ , et al. Pharmaceutical and immuno-logical evaluation of a single-dose hepatitis B vaccine using PLGA microspheres[J]. J Control Release, 2006,112(1):35-42.
doi: 10.1016/j.jconrel.2006.01.012
[11] Shive MS, Anderson JM . Biodegradation and biocompatibility of PLA and PLGA microspheres[J]. Adv Drug Deliv Rev, 1997,28(1):5-24.
doi: 10.1016/S0169-409X(97)00048-3
[12] 练有文, 王晖, 倪少凯 . BALB/c系裸小鼠脏器重量、脏器系数的测定[J]. 中国比较医学杂志, 2006,16(5):166-168.
[13] Zitzmann-Kolbe S, Strube A, Frisk AL , et al. 594 in vivo detection of mammary tumor and its lung metastases in the 4T1 metastasis mouse model by PET imaging using [F-18]-D-FMT (BAY 869596)[J]. EJC Suppl, 2010,8(7):186-187.
[1] LI Wei-hao,LI Wei,ZHANG Xue-min,LI Qing-le,JIAO Yang,ZHANG Tao,JIANG Jing-jun,ZHANG Xiao-ming. Comparison of the outcomes between open and hybrid approaches in the treatment of thoracoabdominal aortic aneurysms repair [J]. Journal of Peking University (Health Sciences), 2022, 54(1): 177-181.
[2] Zheng-da ZHU,Yan GAO,Wen-xiu HE,Xin FANG,Yang LIU,Pan WEI,Zhi-min YAN,Hong HUA. Efficacy and safety of Nocardia rubra cell wall skeleton for the treatment of erosive oral lichen planus [J]. Journal of Peking University (Health Sciences), 2021, 53(5): 964-969.
[3] Yan-fang JIANG,Jian WANG,Yong-jian WANG,Jia LIU,Yin PEI,Xiao-peng LIU,Ying-fang AO,Yong MA. Mid-to-long term clinical outcomes and predictors after anterior cruciate ligament revision [J]. Journal of Peking University (Health Sciences), 2021, 53(5): 857-863.
[4] Xiao LI,Jia-zeng SU,Yan-yan ZHANG,Li-qi ZHANG,Ya-qiong ZHANG,Deng-gao LIU,Guang-yan YU. Inflammation grading and sialoendoscopic treatment of131I radioiodine-induced sialadenitis [J]. Journal of Peking University (Health Sciences), 2020, 52(3): 586-590.
[5] Ze-chuan YANG,Chao-xu LIU,Yang LIN,Wei-hua HU,Wen-jian CHEN,Feng LI,Heng ZENG. All levels miniplate fixation and a modified hybrid fixation method in expansive open-door cervical laminoplasty: a retrospective comparative study [J]. Journal of Peking University(Health Sciences), 2019, 51(1): 187-193.
[6] Wen-zhe YOU,Gui-li DOU,Bin XIA. Two-year outcomes and the influence factors of indirect pulp treatment in primary teeth: a retrospective study [J]. Journal of Peking University(Health Sciences), 2019, 51(1): 65-69.
[7] Xin yi LI,Jin xia ZHAO,Xiang yuan LIU. Diagnosis and treatment of antiphospholipid antibody:related recurrent spontaneous abortion and analysis of therapeutic drugs and pregnancy outcome in 75 patients with antiphospholipid syndrome [J]. Journal of Peking University(Health Sciences), 2018, 50(6): 956-961.
[8] Li-ying GUO,Xiao-xin LIU,Zi-yuan LI,Xiao-ya QIN,Ze-yang FAN,Zhen-zhen LI,Hai-tao GUAN,Li SONG,Ying-hua ZOU,Tian-yuan FAN. Preparation and evaluation of blank and doxorubicin loaded poly (acrylic acid) microspheres for embolization [J]. Journal of Peking University(Health Sciences), 2018, 50(6): 1070-1077.
[9] ZHANG Ming-ming, ZHENG Ying-dong, LIANG Yu-hong. A prognostic model for assessment of outcome of root canal treatment in teeth with pulpitis or apical periodontitis#br# [J]. Journal of Peking University(Health Sciences), 2018, 50(1): 123-130.
[10] LI Xu, LI Feng-long, LU Yi, ZHU Yi-ming, GUO Si-yi, LI Yi-jun, JIANG Chun-yan. Clinical study on locking plate for the treatment of non-osteoporotic complex proximal humeral fractures [J]. Journal of Peking University(Health Sciences), 2017, 49(5): 855-860.
[11] ZHANG Wei-yu, ZHANG Xiao-peng, HU Hao, CHEN Jing-wen, LIU Xian-hui, XU Ke-xin. Analysis of outcomes of tension-free mid-urethral sling procedure in women with mixed urinary incontinence [J]. Journal of Peking University(Health Sciences), 2017, 49(4): 638-642.
[12] FAN Hua, LI Han-zhong, XU Wei-feng, JI Zhi-gang, ZHANG Yu-shi. Surgery treatment of ectopic adrenocorticotrophic hormone syndrome [J]. Journal of Peking University(Health Sciences), 2017, 49(4): 652-656.
[13] ZHANG Yong-jin, LI Jia, QI Ke, XUE Chen-chen, XU Wei-dong. Comparison of efficacy and safety between the anterior and the posterior approaches to total hip arthroplasty [J]. Journal of Peking University(Health Sciences), 2017, 49(2): 201-205.
[14] LV Ming, ZHANG Jin-qing, WANG Xing-shan, HUANG Ye, LI Wei, ZHANG Chun-yu. Surgical technique and early clinical outcomes of direct anterior approach to total hip arthroplasty [J]. Journal of Peking University(Health Sciences), 2017, 49(2): 206-213.
[15] CUI Yun-peng, MI Chuan, SHI Xue-dong, WANG Bing, PAN Yuan-xing, LIN Yun-fei. Clinical characteristics and prognosis of cultured negative pyogenic spondylitis [J]. Journal of Peking University(Health Sciences), 2017, 49(2): 226-230.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
[1] . [J]. Journal of Peking University(Health Sciences), 2009, 41(4): 456 -458 .
[2] . [J]. Journal of Peking University(Health Sciences), 2009, 41(2): 125 -128 .
[3] . [J]. Journal of Peking University(Health Sciences), 2009, 41(2): 135 -140 .
[4] . [J]. Journal of Peking University(Health Sciences), 2009, 41(2): 158 -161 .
[5] . [J]. Journal of Peking University(Health Sciences), 2009, 41(2): 217 -220 .
[6] . [J]. Journal of Peking University(Health Sciences), 2009, 41(1): 52 -55 .
[7] . [J]. Journal of Peking University(Health Sciences), 2009, 41(1): 109 -111 .
[8] . [J]. Journal of Peking University(Health Sciences), 2009, 41(3): 297 -301 .
[9] . [J]. Journal of Peking University(Health Sciences), 2009, 41(5): 599 -601 .
[10] . [J]. Journal of Peking University(Health Sciences), 2009, 41(5): 516 -520 .
Copyright © Journal of Peking University (Health Sciences), All Rights Reserved.
Powered by Beijing Magtech Co. Ltd